ESR1 and breast carcinoma: Consistent with our data, others have suggested that SERDs can differ in their ability to degrade ER in ER+ breast cancer cell lines, and that this correlates with a partial agonist phenotype and poorer anti-proliferative activity in the cell lines where degradation is compromised (43).